J B Chemicals & Pharmaceuticals : Press Release in relation to acquisition of ‘Razel’ franchise from Glenmark Pharmaceuticals Limited

December 14, 2022

BSE Ltd.

Phiroze Jeejebhoy Towers

Dalal Street

Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Press Release

Enclosed please find Press Release the Company proposes to issue in relation to acquisition of 'Razel' franchise from Glenmark Pharmaceuticals Limited.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Ltd.

Sandeep

Anil

Sandeep Phadnis Phadnis

Vice President - Secretarial

& Company Secretary

Digitally signed by Sandeep Anil Phadnis

DN: c=IN, o=Personal, 2.5.4.20=3cf6eb0200f976a58369e39f de8b8876481484d38598145f6e21f4 46bb743f2e, postalCode=411038, st=Maharashtra, serialNumber=cc500fdd638e71336fc 58b204e2ba05ea7c4ade49b8fe438e 8f254c300dec735, cn=Sandeep Anil Phadnis

Date: 2022.12.14 16:28:31 +05'30'

Press Release

JB Pharma to acquire the entire Razel (Rousvastatin) franchise from

Glenmark Pharmaceuticals Ltd

• The acquisition marks JB Pharma's entry into the 'Statin' segment which is the largest group in the cardiac therapy
• Razel ranks among the top 10 brands in the Rousvastatin molecule category in the country

Mumbai, India; December 14, 2022 - JB Chemicals & Pharmaceuticals ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, entered into an agreement with Glenmark Pharmaceuticals Ltd to acquire the Razel (Rousvastatin) franchise for the India and Nepal region. The transaction is expected to be closed within next two weeks subject to customary closing formalities.

Commenting on the acquisition, Mr. Nikhil Chopra, CEO and Whole Time Director, JB Pharma

said, "We are glad to announce the acquisition of the Razel(Rousvastatin & combinations) franchise from Glenmark Pharmaceuticals, thereby marking JB's expansion into Statins, which is the largest therapeutic segment in cardiology. With this addition, we now have established strong position in statins besides being among the leaders in Hypertension and Heart failure - all the fastest growing therapeutic indications in cardiology." He further added "We see good growth potential from the acquired brands. This acquisition will help us leverage our existing Go-To-Market model focussed for this segment and further strengthen our chronic portfolio."

#####

About JB Pharma

J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of the fastest-growing pharmaceutical companies in India and a leading player in the hypertension and the heart-failure segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5

manufacturers globally in medicated and herbal lozenges. It has seven state -of-the-art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

For more details on J.B. Pharma, please visit www.jbpharma.com

For details of our latest sustainability report, please visit https://jbpharma.com/sustainability-report/

Media Contact	Investor Contact
Mr. Swadeep Srivastava	Mr. Sidharth Ragnekar / Ms. Shruti Joshi
Heal Health PR	CDR India
Tel: [phone]	Tel : [phone]
Email : [e-mail]	Email : [e-mail]
		[e-mail]